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Abstract
Purpose—Adverse childhood experiences (ACEs) are associated with poor adult health and 
immune dysregulation. The impact of ACEs on patients with autoimmune disease is unknown. We 
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compared the prevalence of ACEs in Systemic Lupus Erythematosus (SLE) patients to population-
based survey estimate and investigated relationships between ACEs and SLE outcomes.
Methods—Data derive from the California Lupus Epidemiology Study (CLUES), a sample of 
adult SLE patients. Participants completed a 10-item ACE questionnaire covering 3 domains 
(abuse, neglect, household challenges). We estimated ACEs prevalence in 269 CLUES participants 
compared to 2015 California Behavioral Risk Factor Surveillance System (BRFSS) geographically 
matched respondents, standardized (age, sex, race/ethnicity) to CLUES participant characteristics. 
We examined associations for patient-reported and physician-assessed health status measures with 
overall ACE levels and domains using multivariable linear regression, controlling for socio-
demographics, nephritis, and childhood onset SLE.
Results—Though specific domains varied, overall ACE levels were similar for CLUES and 
BRFSS respondents. Among SLE patients, 63.2% had ≥1 ACE and 19.3% had ≥4. ACEs were 
more prevalent in those who were older, women, Latino or African American, without college 
degrees, and with lupus nephritis. In adjusted models, higher ACE levels and ACE domains were 
associated with worse patient-reported SLE activity, depression, and health status, but were not 
significantly associated with physician-assessed SLE activity, damage, or severity.
Conclusions—Given the association between ACE levels and important patient-reported 
outcomes in SLE, our study reinforces the need for prevention of ACEs in childhood and for 
clinical interventions to promote resilience among adults who have experienced ACEs.
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Introduction
Systemic lupus erythematosus (SLE) is a complex chronic, multisystem autoimmune 
disease. Development of SLE is influenced by genetic susceptibility as well as 
environmental interactions (1–3). Stress has been implicated as a potential trigger of disease 
onset and flares (4–7) as well as chronic disability (8). Exploring how a history of major 
stress, such as childhood abuse and neglect, impacts outcomes may inform the association 
between stress and SLE.
Accelerated inflammation, immune dysregulation, and the onset of rheumatic diseases have 
been described in the context of adverse life events (7,9–14). One form of such events is 
adverse childhood experiences (ACEs) which encompass traumas such as abuse, neglect, 
and household challenges. The seminal ACEs study of adults in a large health management 
organization (Kaiser Permanente) found that ACEs were common (15), with a dose response 
for number of ACEs and negative adult health outcomes (16). Population-based studies show 
that a large percentage of adults experienced ACEs. For example, in a large prevalence study 
of ACEs in 2018 from the 2011–2014 Behavioral Risk Factor Surveillance Surveys 
(BRFSS)—state-level population-based surveys that included an ACE questionnaire in 23 
states—more than 60% of respondents recalled at least one ACE and >15% more than four, 
prior to age 18 (17).
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For individuals with autoimmune disease, the prevalence of ACEs and the association with 
disease status are not known. We aimed to determine ACE prevalence among patients with 
known SLE in comparison with population-based participants and to examine the 
association between ACEs with patient-reported and physician-assessed health status.
Patients and Methods
Data Source
This is a cross-sectional analysis of data derived from the California Lupus Epidemiology 
Study (CLUES), a prospective longitudinal sample of individuals with SLE. Briefly, starting 
in 2015, participants for CLUES were recruited through the California Lupus Surveillance 
Project, which used outpatient, hospital, and laboratory records to identify all SLE patients 
residing in San Francisco County from 2007–2009 (18). Additional participants in the 
geographic region were identified through academic and community rheumatology clinics, 
and from earlier studies of genetic risk factors for SLE outcomes (19,20). SLE diagnoses 
were confirmed by study physicians based on (a) ≥4 of the 11 American College of 
Rheumatology (ACR) revised criteria for the classification of SLE (21,22), (b) meeting 3 of 
the 11 ACR criteria with a documented rheumatologist’s diagnosis of SLE, or (c) a 
confirmed diagnosis of lupus nephritis. This combined definition of SLE has been used in 
prior population-based studies (20).
Study procedures included an in-person research clinic visit, which comprised collection and 
review of medical records prior to the visit, a history and physical examination conducted by 
a physician specializing in lupus, collection of clinical labs and stored biospecimens, and a 
structured interview with questionnaires administered by a research assistant. Research 
clinic visits and interviews were conducted in English, Spanish, Cantonese, or Mandarin. A 
total of 332 SLE patients completed the baseline in-person CLUES study visit.
Variables
Identification of ACEs—To quantify the lasting effects of childhood trauma, an ACE 
questionnaire was introduced in 1998 (15). Multiple iterations of ACE questionnaires have 
been used since that time; one version was validated for use by the BRFSS (23).
CLUES: Participants completed a 10-item ACE questionnaire covering three domains: 
household challenges (five items), neglect (two items), and abuse (three items). The 
questionnaire was completed on paper in English or Spanish. For each ACE question, a 
response of “yes” was equivalent to a score of 1; a response of “no” or a skipped response 
was treated as a score of zero. Thus, overall ACE scores range from 0 – 10 with higher 
scores reflecting greater ACE exposure. The overall ACE score, the sum of the responses to 
ACE questions, was categorized into 4 groups (0, 1, 2–3, and ≥4) to derive the ACE level. 
Scores ≥4 denote severe exposure to ACEs (16). Throughout the text, ‘overall ACE score’ 
refers to the sum of individual ACE question items (0 – 10); ‘ACE level’ reflects one of 4 
categorized ACE scores (0, 1, 2–3 or ≥4); ‘ACE domain’ describes question types of 
household challenges, neglect, and abuse.
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A total of 269 completed the ACE questionnaire resulting in an 81% (269/332) response 
rate. Chinese speakers (n=23) were excluded because the ACE questionnaire was offered in 
only English or Spanish, 37 did not complete the ACE questionnaire and 3 were excluded 
for missing patient-reported outcomes.
BRFSS: Since 2009, the BRFSS survey includes an optional module in which states can 
administer items of the ACE questionnaire. We analyzed the 2015 California BRFSS survey 
data; 2015 was selected to match the year of CLUES sample initiation. The BRFSS ACE 
questionnaire, administered in English by telephone, differed from the CLUES version in 
several ways. For example, questions about neglect were absent from the 2015 California 
BRFSS ACE questionnaire. The CLUES and BRFSS ACE questions are in Supplemental 
Table 1.
Patient-Reported Outcomes—SLE disease activity was measured with the Systemic 
Lupus Activity Questionnaire (SLAQ) (24,25), a validated measure of SLE disease activity 
(range 0–44). The Brief Index of Lupus Damage (BILD) was used to estimate organ damage 
(26). The BILD is a proxy for the physician-assessed Systemic Lupus International 
Cooperating Clinics/American College of Rheumatology Damage Index (SDI) (27), and 
consists of 28 items capturing information on 26 SDI items including determinations of 
important comorbid conditions such as diabetes as well as cardiovascular disease and events 
(range 0 – 6). Depressive symptoms were measured with the eight-item version of the 
Patient Health Questionnaire (PHQ; range 0 – 24) (28). PHQ items correspond to the DSM-
IV diagnostic criteria for depression. We assessed physical function with the National 
Institutes of Health Patient-Reported Outcomes Measurement Information System Physical 
Function measure (PROMIS-PF) (29). PROMIS-PF is a 10-item subscale (range 14 – 62) 
with a population mean of 50 and standard deviation of 10 (30). The Physical Component 
Score (PCS), calculated from the Medical Outcomes Study 36-Item Short-Form Health 
Survey (SF-36), was examined as a composite generic measure of physical health status with 
a population mean of 50 and a standard deviation of 10 (31). For measures of disease 
activity (SLAQ), damage (BILD), and depression (PHQ), higher scores reflected worse 
outcomes. For physical function (PROMIS-PF) and generic health status (SF-36 PCS), 
higher scores reflected better outcomes.
Physician-Assessed Status—The Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI) (32) is a frequently used measure of disease activity that ranges from 0 – 
105. The Systemic Lupus Collaborating Clinics/American College of Rheumatology 
Damage Index (SDI) (27) is a measure of organ damage over time (range 0 – 47). The Lupus 
Severity Index (LSI) (33) is a validated tool that utilizes ACR criteria and sub-criteria for 
SLE and predicts morbidity and mortality (range 0 – 100). All physician-assessed outcomes 
were collected by study rheumatologists during the in-person study visit. For each 
instrument, higher scores represent poorer outcomes.
Covariates—We considered potential correlates of SLE outcomes and selected the 
following baseline characteristics (i.e., collected at the initial interview): age, sex, race/
ethnicity (Latino of any race, Non-Hispanic White, Non-Hispanic African American, Asian/
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Pacific Islander, Other), pediatric onset disease prior to age 18 (yes/no), lupus nephritis (yes/
no), and educational attainment (high school or less, some college/associate degree, college 
graduate).
Statistical Analyses
Comparison with the geographically matched population—To increase 
comparability of ACE prevalence estimates from the BRFSS and the CLUES sample, we 
standardized BRFSS estimates to the age- (18–37, 38–53, >54 years), sex-, and racial/ethnic 
distribution to 269 CLUES participants. The BRFSS sample was also limited to the 
California counties represented in the CLUES sample (the San Francisco Bay Area), 
resulting in a sample size of 6,107 BRFSS respondents. Differences in the item and domain 
responses were calculated using a 2-sample t-test, assuming independence of the BRFSS and 
CLUES samples. For these comparisons, we excluded the neglect domain items from 
calculation of CLUES patients’ ACE scores because neglect data were not collected in 
BRFSS; scores for both samples ranged from 0–8. In all analyses of BRFSS data, we 
accounted for its complex design (34).
Analysis of ACE among CLUES Sample—Descriptive statistics were calculated for 
the total sample and by overall ACE level categories. Differences in group characteristics 
were evaluated using linear contrast trend tests for continuous (35) and chi-square tests for 
categorical variables. We developed unadjusted and multivariable linear regression models 
of patient-reported and physician-assessed measures to examine differences in these 
outcomes by overall ACE level (0, 1, 2–3, ≥4). Adjustment variables were age, sex, race/
ethnicity, pediatric onset disease, and educational attainment. Next, we looked at differences 
in the patient-reported and physician-assessed measures by ACE domain through separate 
models for each domain where respondents were categorized into the following 3 groups: ≥1 
items in the domain, 0 items in the domain but ≥1 items in other domains, and 0 ACEs (i.e., 
no items in any domain; referent group). We created a referent group comprising those who 
were not exposed to any ACEs to isolate the specific effects of the domain of interest. The 
ACE domain models were run with and without adjustment for the variables listed above. 
All statistical tests were conducted at α = 0.05. Analyses were performed with Stata 
(StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp 
LLC).
Results
Estimates for overall ACE levels and ACE domains from CLUES and BRFSS are shown in 
Table 1. The distribution of overall ACE levels was similar for the two study populations 
(p=0.42) with severe ACE exposure (i.e., ACEs ≥ 4) of 15.2% in CLUES and 17.2% in 
BRFSS). In this table, the neglect domain was excluded from the overall CLUES ACE 
levels, to be consistent with the BRFSS questionnaire. For analysis of ACEs by domain, the 
prevalence of household challenges overall was similar for the CLUES and BRFSS 
populations (53.0% vs. 49.5%, p=0.32). However, there was a higher prevalence of abuse in 
the BRFSS population than in CLUES patients (45.2% vs 34.2%, p<0.001). For the specific 
domain items, there were more reports of emotional abuse (36.5% vs 21.6%, p<0.001) and 
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domestic violence (21.0% vs 10.0%, p<0.001) in BRFSS than CLUES. In contrast, sexual 
abuse was reported somewhat more frequently by CLUES patients than BRFSS participants 
(19.0% vs 14.1%, p=0.06). Among the CLUES participants, approximately one-quarter 
reported neglect, with most of that being emotional neglect (lack of care and support) rather 
than physical deprivation.
Table 2 shows baseline characteristics among the 269 CLUES participants who completed 
the ACE questionnaire. Mean age was 45.2 years, 89.6% were women and 16.4% were 
diagnosed with SLE in childhood, consistent with the epidemiology of SLE. Reflecting the 
diverse population of the study area, 31.6% were Non-Hispanic White, 29.4% Asian/Pacific 
Islander, 25.7% Latino, 11.9% Non-Hispanic African American, and 1.5% Other. The 
median overall ACE score, which includes neglect, was 1, and 19.3% had ≥4 ACEs. Those 
with ACE scores > 0 were older, more likely to be women, of Hispanic ethnicity or African 
American race, more likely to have less than a four-year college degree, and more likely to 
have a history of SLE nephritis than those with ACE scores = 0. Pediatric onset disease was 
less common among those with ACE scores > 0. There were no differences in ACE scores 
by disease duration.
Analysis of patient-reported health outcomes by overall ACE level demonstrated a dose-
response where patient-reported SLE disease activity, damage, depression were higher, and 
physical function and health status were lower, with increasing ACE levels. These 
relationships persisted after adjusting for age, sex, race, childhood onset, and educational 
attainment (Table 3), although the PROMIS-PF measure of functioning and the BILD score 
measuring damage were not statistically significant. After multivariable adjustments, for 
each of the three domains, ACE exposure (household challenges, neglect, abuse) was 
consistently associated with poor patient-reported outcomes, with all but BILD reaching 
statistical significance. In contrast with patient-reported outcomes, multivariable adjusted 
analyses of physician-assessed measures (Table 4) did not show the same trends for ACE 
level or any of the ACE domains.
Discussion
This is the first study to identify the prevalence of ACEs in persons with SLE and to 
examine associations between ACEs and health status in a sample with SLE. Analyses 
suggest that ACEs are common in persons with SLE, and that ACE scores for overall ACE 
level and all 3 ACE domains were significantly associated with worse patient-reported 
outcomes (SLAQ, PHQ, SF-36 PCS) in a dose-response pattern. These associations 
persisted after adjustment for age, sex, race/ethnicity, disease onset <18 years, and 
educational attainment. Patients who report life stressors often perceive worse SLE 
symptoms (36,37). Although ACEs were not significantly associated with SLE outcomes 
deriving from physician assessments, they may play a role in patient perception of disease 
activity, depression, and overall health status.
In the more than twenty years that the ACE questionnaire has been used in population 
studies, multiple studies have revealed that having a history of ACE exposures is associated 
with poor long-term health and impaired quality of life in adulthood (12,16,38). Estimates 
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from large surveys (Kaiser Permanente and BRFSS in multiple states) conducted from 
1998–2014 showed a range in prevalence of ACE exposures; 50.5–63.9% of individuals had 
ACE scores ≥1 and 6.2–15.8% had ACE scores ≥4. ACE domains such as abuse and 
household challenges were also frequently documented in these studies (abuse 
prevalence=10.6–35.0%; household challenge prevalence=3.4–26.9%, respectively) (15–
17,39,40). We found that for CLUES and BRFSS participants, overall ACE levels were 
generally comparable: more than 60% identified at least 1 ACE (60.4 and 65.6%, 
respectively) and more than 15% indicated ≥4 ACEs (15.0 and 19.6%, respectively). The 
BRFSS respondents reported significantly more domestic violence, overall abuse, and 
emotional abuse than the CLUES sample.
The similar prevalence of overall ACE levels and the high prevalence of ACEs for specific 
domains among BRFSS respondents is inconsistent with prior findings of an association 
between immune dysregulation and childhood trauma (12). For example, we found a trend 
toward higher exposure to childhood sexual abuse among the SLE sample than in the 
population-based participants, though this did not reach statistical significance. There may 
be several reasons for these results. One possibility is potential selection bias in the CLUES 
sample as patients with a childhood history of low socioeconomic status and/or more severe 
disease may be less able to participate in research studies due to social stressors (41); 
furthermore, the BRFSS is designed to be representative of the civilian, non-institutionalized 
population for the geographic target area. Survival bias may also be present here if those 
with more severe ACE exposure were more susceptible to potentially life-threatening SLE 
manifestations. Thus, those with the most exposure to ACEs and those with the most severe 
disease may not be represented in the CLUES sample. Finally, recall bias may be differential 
across the two data sources because the CLUES ACE questions are more specific than the 
BRFSS questions which may have prompted increased reporting of ACEs among CLUES 
respondents.
There is mounting evidence that links a history of life stressors with autoimmune disease 
onset and flares (13,42,43). A recent retrospective cohort of primarily male veterans 
(Operation Enduring Freedom, Operation Iraqi Freedom, Operation New Dawn Roster) and 
a prospective trial of women nurses (Nurses’ Health Study II) found that individuals with 
post-traumatic stress disorder (PTSD) had an increased likelihood of a new diagnosis of SLE 
(Adjusted Rate Ratio=1.65, 95% CI 1.14–2.24, p<0.008; Hazard Ratio (HR)=2.94 95% CI 
1.19–7.26, p<0.05, respectively) (42,43). Trauma exposure, regardless of PTSD status, was 
strongly associated with incident autoimmune disease (HR=2.83, 95% CI 1.29–6.21, p< 
0.01) (43). Our findings align with these recent associations between stress and SLE in 
suggesting that ACEs may result in poorer patient-reported outcomes among those with 
autoimmune disease.
We showed a significant association between high overall ACE score level and poor patient-
reported disease activity, depression, and overall health status. Depression across the 
lifespan has been reported in those with high ACE exposure and SLE diagnosis (44). A 
previous study found a strong inverse relationship between ACEs and health status in 
adulthood as measured by the SF-36 (45), that corresponds to findings in this study. 
Therefore, there may be value for clinicians to regularly screen SLE patients for ACEs, 
DeQuattro et al. Page 7
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2020 November 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
along with depression, and overall perceived health status, whether they meet the individual 
early or later in the disease course. There may be particular utility in screening near the time 
of diagnosis to identify those at higher risk for subsequent poor outcomes.
Greater presence of household challenges, neglect, and abuse were significantly associated 
with worse patient reported outcomes across all patient-reported measures except SLE 
damage. These findings support the notion by Dong et al. that ACEs often occur 
concurrently; i.e., self-report of an ACE in one domain may increase the likelihood that an 
individual has a history of additional ACEs, possibly in another domain (46). This suggests a 
parallel concept seen in this study: if a history of ACEs affects one patient-reported outcome 
measure, multiple measures may in fact be impacted. Therefore, examination of a 
constellation of patient-reported outcomes permits a more granular understanding of ACEs’ 
effects on SLE patient experience which in turn may enable more tailored strategies for 
coping and resilience. For example, the strong relationship with ACE levels and current 
depression, as measured through the PHQ, suggests that those with depression may benefit 
from learning behavioral coping strategies.
Patient-reported outcome measures have long been recognized as critical to capture the 
patient experience in parallel with disease management (47), and our data suggest that the 
ACE questionnaire aligns with health status in SLE patients. However, while we found a 
strong association of ACE history with patient-reported outcomes, we did not find an 
association with physician-assessed outcomes. This pattern is consistent with other studies 
in the SLE literature, whereby quality of life and other patient-reported outcomes often show 
little relationship to physician-assessed measures of disease activity and damage (48,49).
This disconnect may stem from differences in the way items are explored in physician-
assessed versus patient-reported questionnaires. Physician-assessed items focus on 
quantifying overt physical findings on exam, history, or laboratory results. In contrast, 
patient-reported outcomes expand on how a disease affects daily life activities like walking, 
bathing, and work. For example, associations of arthritis and poor sleep, anhedonia, or pain 
are not measurable by the clinician-assessed SLEDAI but are identified by patient-reported 
surveys like the SLAQ, SF-36 PCS, and PHQ. Physician-assessments quantify a physical 
impairment while patient-reported outcomes include the patient’s experience of that physical 
impairment. Therefore, patient-reported measures are more suited to effectively capture 
ACE impact on overall health in SLE patients than physician-assessed outcomes and should 
continue to be utilized to understand ACEs in the context of chronic illness.
Strengths of this study include a diverse sample with an array of clinically relevant outcome 
measures. There are several limitations as well. First, as noted above, our sample may not be 
representative of patients with the most severe SLE due to either presence of fewer patients 
with clinically active disease or survival bias. Second, while there is ongoing research to 
investigate links between ACE and poverty, the CLUES questionnaire did not include 
measures of childhood socioeconomic status, for example, whether the family received 
government benefits or parental education levels. However, patient educational attainment 
was used as a proxy for socioeconomic status that would pre-date disease onset in most 
individuals; all models of the association between ACEs and disease status controlled for 
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educational attainment. Third, reporting of ACEs may vary for different reasons. We 
previously suggested reporting may depend on specificity of ACE questionnaires. On the 
other hand, there may be overall underreporting of ACEs, due both to reluctance to report 
childhood traumatic experiences in adulthood (16) as well as to limitations of the ACE 
questionnaire itself, which excludes such adverse experiences as accidental/injurious trauma, 
bullying, discrimination, and community-level trauma. Additionally, the ways in which race, 
ethnicity, and culture play a role in SLE and ACEs reporting are unclear and deserve future 
dedicated study. Furthermore, it is not possible to rule out additional sources of bias, such as 
recall bias, in which people with poor health are more likely to report prior negative 
experiences. We also cannot confirm causal associations between remote ACEs and disease 
outcomes. However, there is some evidence for a causal association, including the lasting 
effects of ACEs and the graded associations between ACEs and poor adult health (16).
Conclusion
While the prevalence of adverse childhood experiences varies by domain, and in some 
domains BRFSS respondents actually reported more ACEs, overall, ACEs are frequently 
reported both in individuals with SLE and in the population at large. Higher overall ACE 
score levels and scores in each domain are associated with greater patient-reported SLE 
activity and damage, higher levels of depressive symptoms, poorer physical function, and 
worse overall health status. Clinical measures of activity, damage, and severity do not 
parallel patient-reported trends of cumulative ACEs. Cumulative ACE exposure may be 
relevant to patient perceptions of SLE activity, depression, and physical function. Although 
this study exposes relationships between ACEs and patient-reported health outcomes, 
definitive means to successfully prevent or repair long-term effects of ACEs are less clear. 
Prevention of ACEs and promotion of safe, stable, nurturing relationships and environments 
for children are vital (50). This work lends support for ACE prevention during childhood as 
well as clinical and mental health interventions that focus on resilience in adulthood after a 
history of ACE has been established.
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Significance & Innovations
• This study is the first to assess ACE levels in an SLE sample and examine 
SLE outcomes associated with childhood trauma. Findings reinforce the need 
for prevention of ACEs and promotion of resilience-informed clinical 
interventions in those who have experienced ACEs.
• ACEs were common in patients with SLE and a geographically matched 
population.
• Higher ACE levels and presence of ACEs from each domain (abuse, neglect, 
and household challenges) were associated with worse patient-reported 
disease activity, depression, and health status, but not physician-assessed 
measures.
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Table 1.
Comparison of California Lupus Epidemiology Study (CLUES) 2015–2018 participants and California 
Behavioral Risk Factor Surveillance System Survey (BRFSS) 2015 respondents in Adverse Childhood 
Experiences (ACE) levels, domains, and items.
Data Source
CLUES (n= 269) BRFSS1 (n= 6,107) p-value
% (95% Confidence Intervals)
Overall ACE Level2 0.42
  0 39.8 (34.1, 45.8) 37.3 (34.7, 40.0)
  1 23.4 (18.7, 28.9) 21.4 (19.3, 23.7)
  2–3 21.6 (17.0, 26.9) 24.1 (22.0, 26.4)
  ≥4 15.2 (11.4, 20.1) 17.2 (15.5, 18.9)
Domain
 Abuse 34.2 (28.8, 40.1) 45.2 (42.6, 47.9) <0.001
  Emotional 21.6 (17.0, 26.9) 36.5 (34.0, 39.0) <0.001
  Physical 17.1 (13.0, 22.1) 21.6 (19.6, 23.8) 0.08
  Sexual 19.0 (14.7, 24.1) 14.1 (12.2, 16.1) 0.06
 Household Challenges 53.0 (47.0, 58.9) 49.5 (46.9, 52.1) 0.32
  Separation/Divorce 33.1 (27.7, 39.0) 27.3 (25.3, 29.5) 0.06
  Substances in Home 23.0 (18.4, 28.5) 24.2 (22.5, 26.1) 0.66
  Mental Illness in Home 19.0 (14.7, 24.1) 15.2 (13.6, 17.0) 0.14
  Incarcerated Household Member 5.6 (3.4, 9.1) 7.3 (6.4, 8.4) 0.24
  Domestic Violence in Home 10.0 (7.0, 14.3) 21.0 (19.1, 23.1) <0.001
 Neglect 24.2 (19.4, 29.7) --
  Emotional 23.4 (18.7, 28.9) --
  Physical 3.7 (2.0, 6.8) --
1
BRFSS responses account for complex survey design and are standardized to CLUES demographic distribution on age (18–37, 38–53, >54 years), 
sex, and race/ethnicity.
2
BRFSS ACE questionnaire does not include two “Neglect” items. Overall ACE levels for CLUES patients do not include the two neglect items.
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Table 3.
Patient-reported SLE activity and damage, depression, physical function and quality of life among 269 
California Lupus Epidemiology Study participants, by Adverse Childhood Experiences (ACE) level and 
domain from linear regression models adjusted for covariates1
Patient-Reported Measures
Overall ACE 
Level
SLAQ Disease 
Activity
BILD Disease 
Damage
PHQ Depression PROMIS-PF Physical 
Function
SF-36 PCS Health 
Status
Adjusted means (95% CI)
 0 7.7 (6.3–9.1) 1.6 (1.2–2.1) 5.1 (4.1–6.1) 48.9 (47.2–50.7) 44.0 (41.9–46.2)
 1 8.2 (6.5–9.9) 2.0 (1.4–2.5) 5.4 (4.1–6.7) 48.4 (46.2–50.6) 42.6 (39.9–45.3)
 2–3 9.5 (7.8–11.2) 1.9 (1.3–2.4) 7.3 (6.1–8.6) 46.9 (44.7–49.2) 41.1 (38.4–43.8)
 ≥4 13.1 (11.2–15.0) 2.6 (2.0–3.2) 8.1 (6.7–9.5) 44.8 (42.4–47.2) 38.0 (35.1–41.0)
p-value <0.001 0.10 0.01 0.050 0.01
ACE Domain
None 7.7 (6.3–9.1) 1.6 (1.2–2.1) 5.1 (4.1–6.1) 48.9 (47.2–50.7) 44.0 (41.9–46.2)
Household 
Challenges
10.0 (8.9–11.2)* 2.1 (1.8–2.5) 6.8 (6.0–7.7)* 46.5 (45.1–48.0)* 40.7 (38.9–42.4) *
Neglect 10.9 (9.2–12.5)* 2.0 (1.4–2.5) 7.6 (6.4–8.8)* 45.7 (43.6–47.9)* 39.7 (37.1–42.3)*
Abuse 11.7 (10.3–13.1)* 2.2 (1.8–2.7) 7.7 (6.7–8.7)* 46.1 (44.3–48.0)* 39.2 (37.0–41.4)*
SLAQ - Systemic Lupus Activity Questionnaire; BILD - Brief Index of Lupus Damage; PHQ - Patient Health Questionnaire depression scale; 
PROMIS PF – Patient-Reported Outcomes Measurement Information System Physical Function; SF-36 PCS – Short Form, Physical Component 
Scale.
1Adjusted for age, gender, race, disease onset <18 years, education level.
Domain effects estimated in separate models, using a 3-level variable: 1+ items in the given domain; 1+ items in any other domain (not shown in 
table); no items (i.e., ACE=0).
*p<0.05 for comparison of domain effect to ACE=0.
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Table 4.
Physician-assessed outcomes of activity, damage and severity by Adverse Childhood Experiences (ACE) level 
and domain, adjusted models
Physician-Assessed Outcomes
Overall ACE Level SLEDAI Disease Activity SDI Disease Damage LSI Disease Severity
Adjusted means (95% CI)
 0 2.5 (1.9–3.2) 1.7 (1.3–2.1) 6.9 (6.6–7.2)
 1 2.6 (1.8–3.4) 2.2 (1.7–2.7) 7.0 (6.6–7.4)
 2–3 3.7 (2.9–4.5) 2.1 (1.6–2.6) 6.8 (6.4–7.2)
 ≥4 2.4 (1.6–3.3) 1.9 (1.3–2.4) 6.4 (6.0–6.8)
p-value* 0.08 0.49 0.18
ACE Domain
None 2.5 (1.9–3.2) 1.7 (1.3–2.1) 6.9 (6.6–7.2)
Household Challenges 3.0 (2.5–3.6) 2.1 (1.8–2.4) 6.8 (6.5–7.0)
Neglect 2.6 (1.9–3.4) 1.7 (1.2–2.2) 6.7 (6.3–7.1)
Abuse 3.0 (2.4–3.7) 2.1 (1.6–2.5) 6.7 (6.4–7.0)
SLEDAI - Systemic Lupus Erythematosus Disease Activity Index; SDI - Systemic Lupus Collaborating Clinics Damage Index; LSI - Lupus 
Severity Index
1Adjusted for age, gender, race, disease onset <18 years, education level.
Domain effects estimated in separate models, using a 3-level variable: 1+ items in the given domain; 1+ items in any other domain (not shown in 
table); no items (i.e., ACE=0).
*p<0.05 for comparison of domain effect to ACE=0.
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